Trump health pick wary of government drug price negotiations
President Donald Trump's pick for health secretary is telling senators he's wary of a broad government role in negotiating prescription drug prices.
Alzheimer's will cost the US $1 trillion: Merck CEO
Alzheimer’s is going to cripple the U.S., if a disease modifying agent isn’t soon discovered, Merck’s (NYSE:MRK) CEO Ken Frazier told FOX Business’ Maria Bartiromo on ‘Mornings with Maria.”
Mylan CEO sees faster drug approvals, cheaper generics with FDA Chief Gottlieb
Mylan CEO Heather Bresch tells FOX Business the company took care of the EpiPen problem and is focusing on new drugs in its pipeline.
Novo Nordisk revises up offer for Ablynx to $3.1 billion
Danish drugmaker Novo Nordisk has revised up its offer for Belgian biotech company Ablynx as it looks to find growth opportunities beyond its core business.
$11 billion biotech binge fuels forecasts of 2018 M&A surge
An $11 billion burst of biotech bids in just four days has fueled expectations of a 2018 surge in life science deals as large drugmakers shop for promising assets from smaller rivals.
Tax refunds spur health care spending as consumers delay care
American families are putting off health care treatments until their tax refund is delivered to their bank accounts, according to a new study.
Biotech a boost for investors' portfolios in 2018?
Biotech sector watch
Novo Nordisk's $3.1B Ablynx bid rejected by Belgian biotech
Denmark's Novo Nordisk, the world's biggest maker of insulin, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday as it seeks to bolster its treatments for rare blood disorders.
Biotech innovation driving health care advances
Investing in biotech
Celgene to buy Impact Biomedicines for up to $7B
U.S. biotech pharmaceutical firm Celgene Corp said on Sunday that it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.
Pfizer ends research for new Alzheimer's, Parkinson's drugs
Pfizer is abandoning research to find new drugs aimed at treating Alzheimer's and Parkinson's disease, the U.S. pharmaceutical company announced on Saturday.
Takata adds 3.3 million air bag inflators to massive recall
Japanese air bag maker Takata is recalling another 3.3 million faulty air bag inflators as it continues to expand the largest automotive recall in U.S. history.
Florida hack exposed 30K Medicaid patients' personal data: officials
The state's Agency for Health Care Administration said in a Friday evening news release that one of its employees "was the victim of a malicious phishing email" on Nov. 15.
Romaine lettuce linked to deadly E. coli outbreak
E. coli outbreak linked to romaine lettuce
Sonic and TiGenix climb; Constellation Brands and Sears fall
Stocks that moved substantially or traded heavily Friday: Constellation Brands Inc., down $5.91 to $219.88
5 stocks dominate the Dow's 25K milestone in 2018
A deep dive into the Dow’s record run highlights the players powering the benchmark.
New deal between UPMC, Highmark extends in-network access
Under a new agreement, Highmark health insurance will maintain in-network access to University of Pittsburgh Medical Center hospitals in western Pennsylvania.
Game Changer: The $850,000 blindness drug
The inception of a new drug that offers a cure for a retinol eye disorder is a game changer according to Fox News medical correspondent Dr. Marc Siegel.
This blindness drug costs $850,000
A first-of-its kind genetic treatment for blindness is among the most expensive genetic therapies in the world.
Alphabet health care company gets funding to help Medicaid patients
Cityblock Health said on Thursday it received $20.8 million in a first round of funding from Maverick Ventures, Thrive Capital and Sidewalk Labs, the subsidiary of Alphabet Inc that founded Cityblock.